FibroGen Inc (FGEN) VP Pat Cotroneo Sells 2,851 Shares

FibroGen Inc (NASDAQ:FGEN) VP Pat Cotroneo sold 2,851 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $46.00, for a total transaction of $131,146.00. Following the completion of the transaction, the vice president now owns 183,852 shares of the company’s stock, valued at $8,457,192. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

FibroGen Inc (FGEN) traded up $0.45 during trading on Wednesday, reaching $44.15. 876,746 shares of the company’s stock traded hands, compared to its average volume of 618,791. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen Inc has a 1-year low of $19.25 and a 1-year high of $60.15.

Several research analysts recently issued reports on the stock. BidaskClub lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. ValuEngine lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Stifel Nicolaus reiterated a “buy” rating and issued a $80.00 target price on shares of FibroGen in a research report on Thursday, September 14th. Mizuho assumed coverage on shares of FibroGen in a research report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 target price for the company. Finally, Jefferies Group reiterated a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research report on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $65.67.

Institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund lifted its stake in FibroGen by 24.0% in the second quarter. New York State Common Retirement Fund now owns 67,700 shares of the biopharmaceutical company’s stock worth $2,187,000 after purchasing an additional 13,099 shares during the last quarter. FMR LLC lifted its stake in FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after purchasing an additional 1,641,423 shares during the last quarter. Prudential Financial Inc. lifted its stake in FibroGen by 9.6% in the second quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock worth $14,496,000 after purchasing an additional 39,430 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in FibroGen by 12.2% in the second quarter. The Manufacturers Life Insurance Company now owns 46,284 shares of the biopharmaceutical company’s stock worth $1,495,000 after purchasing an additional 5,022 shares during the last quarter. Finally, Strs Ohio lifted its stake in FibroGen by 15.3% in the third quarter. Strs Ohio now owns 164,900 shares of the biopharmaceutical company’s stock worth $8,871,000 after purchasing an additional 21,900 shares during the last quarter. 57.43% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “FibroGen Inc (FGEN) VP Pat Cotroneo Sells 2,851 Shares” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/12/13/fibrogen-inc-fgen-vp-pat-cotroneo-sells-2851-shares.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply